USE OF A RAPID hCG-BETA-SUBUNIT RADIOIMMUNOASSAY IN ACUTE GYNÆCOLOGICAL EMERGENCIES

Seppälä, Markku; Ranta, Tapio; Tontti, K; Stenman, U H; Chard, Tim

doi:10.1016/s0140-6736(80)90656-x

Cited by 45 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pregnancy tests available at that time had a detection limit of 300-500 IU/L, which was not sensitive enough for diagnosis of early pregnancy and gynecological emergencies 83 . Our group therefore modified the SB6 RIA by shortening the assay time to 2 h. The detection limit was 25 IU/L, which made it possible to detect a pregnancy at the time of the first missed period 84 .…”

Section: Functions Of Tati In Cancermentioning

confidence: 99%

Biomarker development, from bench to bedside

Stenman

2015

Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

Application of laser & photonics in dentistry and medicine has a long history, however, it is still emerging as a new field enabling the application of advanced technology at precise size and levels and the exploitation of novel properties. Many areas of dental/medical device are expected to benefit from photonics including sensors for use in the laboratory , the clinic, and within the human body. For example, the potential uses of laser include the early detection and treatment of disease. These new innovative biomedical pho-tonics include "advanced bioimaging" to push photon-based imaging tools to new limits of resolution and utility for "molecular and cellular imaging" to develop and apply advanced optical diagnostic probes to important problems in molecular and cellular biology, and "biomedical photon-ics" to translate photonics to clinical dentistry/medicine for disease screening, diagnosis and therapy. Launched in April 2015, the Japan Agency for Medical Research and Development （AMED） pursues its assigned mission to fast-track medical research and development in support of humanity. AMED is currently tackling the challenge of reforming Japan＇s funding allocation and evaluation systems. Other significant tasks in fast-tracking the social implementation of research outcomes include rapid diagnosis of undiagnosed diseases, and novel therapeutic interventions for patients. AMED engages in research and development in the field of medicine, establishing and maintaining an environment for this R&D, and providing funding, in order to promote integrated medical R&D from basic research to practical applications, to smoothly achieve application of outcomes, and to achieve comprehensive and effective establishment / maintenance of an environment for medical R&D. Providing a one-stop service for research expenses, AMED consolidates budgets for research expenses, which had previously been allocated from different sources-the Ministry of Education, Culture, Sports, Science and Technology , the Ministry of Health, Labour and Welfare, and the Ministry of Economy, Trade and Industry. AMED aims to achieve the world＇s highest level of medical care / service and to form a society in which people live long, healthy lives by promoting integrated research and development, from basic research to practical application, and by establishing and maintaining an environment therefor, and linking this to various forms of growth in medical R&D. In this special lecture I would introduce a birds-eye view not only AMED supporting R&D program but also FMDIPA activity to develop dental/medical laser device industry, currently being undertaken to overcome the problems facing dental/medical diseases. He has made extensive contributions to the development of the bioengineering profession worldwide through his extensive professional activities and service with the government. He has also extensive experience in working with industry partners. In recognition of his contribution and leadership, he was elected for the initiative member to start up t...

show abstract

Section: Functions Of Tati In Cancermentioning

confidence: 99%

Biomarker development, from bench to bedside

Stenman

2015

Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

show abstract

“…of a single sample from an emergency patient. Results with highly sensitive radioimmunoassay Preliminary results on the clinical application of a 2-hour hCG-RIA test have been encouraging (Seppala et al, 1980~). We report here results of the routine use of the rapid hCG-RIA test in 470 women with gynaecological emergencies.…”

Section: Discussionmentioning

confidence: 92%

Improved Diagnosis of Pregnancy‐related Gynaecological Emergencies by Rapid Human Chorionic Gonadotrophin Beta‐subunit Assay

Seppälä

Ranta

Rutanen

et al. 1981

BJOG

Self Cite

View full text Add to dashboard Cite

Summary A pregnancy‐related disorder was identified by a rapid radioimmunoassay of serum chorionic gonadotrophin (hCG‐RIA) in 122 out of 470 women (26 per cent) with lower abdominal pain or bleeding, while a routine pregnancy test in urine was positive in only 7 per cent of these cases. In 49 patients with ectopic pregnancy the rapid hCG‐RIA was positive in 90 per cent as compared with 13 per cent for the routine pregnancy test. In patients with evidence of intrauterine pregnancy (66 cases) the rapid hCG‐RIA was positive in 98 per cent and the routine pregnancy test in 38 per cent. The clinical sensitivity of the hCG‐RIA was 95 per cent, specificity 96 per cent and predictive value 89 per cent. The test can improve the efficiency of the routine diagnosis of early intra‐ and extrauterine pregnancy‐related disorders.

show abstract

“…The advent of the @-subunit hCG assay has been a major advance in the management of trophoblastic disease (Yuen et d, 1977) and in the early accurate diagnosis of pregnancy (Vaitukaitis et aZ, 1972). This may be useful in the treatment of acute gynaecological emergencies (Seppala, 1980) and could also allow early initiation of therapy so necessary if endocrine causes of abortion are to be treated successfully.…”

Section: Discussionmentioning

confidence: 99%

MATERNAL PLASMA β‐hCG IN EARLY HUMAN PREGNANCY

Harrison

O’Moore

McSweeney

1980

BJOG

View full text Add to dashboard Cite

Summary β‐human chorionic gonadotrophin (β‐hCG) was assayed twice weekly in plasma from 20 subjects from 4 to 16 weeks gestation; 14 of these were normal. There was an initial rise, a plateau at weeks 7 to 9, and a further rise to a maximum at week 11. Levels then dropped steadily to week 16. There was no significant difference when mean levels were subdivided and calculated according to the subsequent sex of the baby. Of the 6 abnormal subjects, the twin pregnancy initially showed normal levels but at week 11 and 13 these were at least one standard deviation above the mean. The plasma β‐hCG levels of the two subjects who aborted were more than one standard deviation below the mean at week 5. Three subjects treated with progestogen therapy had β‐hCG levels which fluctuated within normal limits. The trends of β‐hCG levels were similar to those of plasma hCG levels in the two subjects who had both assays performed but peak times were different. There was considerable within patient and also patient to patient variation in β‐hCG levels.

show abstract

USE OF A RAPID hCG-BETA-SUBUNIT RADIOIMMUNOASSAY IN ACUTE GYNÆCOLOGICAL EMERGENCIES

Cited by 45 publications

References 3 publications

Biomarker development, from bench to bedside

Biomarker development, from bench to bedside

Improved Diagnosis of Pregnancy‐related Gynaecological Emergencies by Rapid Human Chorionic Gonadotrophin Beta‐subunit Assay

MATERNAL PLASMA β‐hCG IN EARLY HUMAN PREGNANCY

Contact Info

Product

Resources

About